lesions. To our knowledge, there has been no previous report of LCV due to duloxetine in the literature. In conclusion, considering this case, neurologists should be aware of duloxetine’s rare but possible and potentially serious cutaneous adverse effect, which is not dose dependent. Disclosure. Financial support: none. Conflict of interest: none. 1
Department of Dermatology, Department of Neurology, 3 Department of Pathology, Namık Kemal University Research Hospital, Poliklinigi Tunca Cad. 100, Yıl mah, Tekirdag, Turkey 2
Gamze ERFAN1 Recep ALP2 Sule ALBAYRAK1 Keriman OGUZ2 Serkan KALAYCI1 Meltem OZNUR3 Mustafa KULAC1
1. Preskorn SH. Duloxetine. J Psychiatr Pract 2004; 10: 375-85. 2. Gross CM, Klöcker M, Jakob T, Klecha D. Dermatological side effects during therapy with serotonin noradrenaline reuptake inhibitors. Nervenarzt 2008; 79: 1307-9. 3. Vey EL, Kovelman I. Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey. J Forensic Leg Med 2010; 17: 175-85. 4. Mallinckrodt CH, Prakash A, Andorn AC. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006; 40: 33748. 5. Strawn JR, Whitsel R, Nandagopal JJ, Delbello MP. Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine. J Child Adolesc Physchopharmacol 2011; 21: 91-2. 6. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111-8. 7. Arimone Y, Bidault I, Dutertre J-P. Update of the French drug reaction assessment method. Therapie 2011; 66: 517-25. doi:10.1684/ejd.2014.2491
Changes of serum lipocalin-2 and retinol binding protein-4 levels in patients with psoriasis and Behc¸et’s disease The correlation between psoriasis, Behc¸et’s Disease (BD) and metabolic syndrome (MetS) is related to chronic inflammation [1, 2]. It is suggested that the inflammation that is caused by increased cytokines leads to an increase in insulin resistance and MetS. It has been shown that Lipocalin-2 (LCN-2), and Retinol-binding protein-4 (RBP-4) are related to obesity and insulin-resistance in humans [3, 4]. The current study aimed to investigate LCN-2 and RBP-4 levels in psoriasis and BD, which are known to have activity in insulin resistance and MetS formation. A total of 60 patients, 30 with psoriasis vulgaris and 30 with BD, admitted to the dermatology policlinics, and 30 healthy volunteers, 15 males and 15 females, who were matched according to body mass index (BMI) and age, were included in the study. The controls were individuals admitted to the EJD, vol. 25, n◦ 2, March-April 2015
hospital for an annual check-up who had no systemic and neurological diseases in their past medical and family history, systemic drug use, alcohol or narcotic drug use, and who were similar with the study group according to age, gender, and BMI. Serum LCN-2/NGAL and RBP-4 levels were determined using commercial kits with the sandwich ELISA method (for LCN-2/NGAL, BOSTER trademark, catalogue number: EK0853; for RBP-4, Assaypro trademark, catalogue number: ER3005-1). Demographic, clinical and laboratory characteristics of the psoriasis and BD patients and the control group are demonstrated in table 1. Serum LCN-2 levels in patients with psoriasis and BD were found to be statistically higher when compared to the controls (p = 0.01 and p0.05 p>0.05 p>0.05 a p = 0.006 p>0.05
HDL-cholesterol* (mg/dl) VLDL-cholesterol* (mg/dl)
47.90 ± 15.08 24.46 ± 13.92
44.64 ± 10.30b 29.33 ± 12.80c
51.18 ± 11.80b 20.13 ± 9.16c
b
Total cholesterol* (mg/dl) HbA1c* (%)
189.03 ± 33.753d 4.73 ± 0.43
175.23 ± 45.33 4.67 ± 0.33e
166.13 ± 28.82d 4.88 ± 0.38e
d
Insulin* (IU/mL) C-peptid* (ng/mL) HOMA-IR values*
5.48 ± 3.84f 2.01 ± 0.68 1.14 ± 0.79
7.66 ± 6.52 2.40 ± 1.10 1.46 ± 1.36
9.17 ± 5.17f 2.02 ± 0.90 1.88 ± 1.24
f
LCN-2* (pg/mL)
5729.06 ± 1075.56g,h
189.53 ± 2166.36h,ı
4623.37 ± 21.78.38g,ı
g
RBP-4* (ng/mL)
3284.33 ± 1028.87j
2973.00 ± 699.57k
2482.41 ± 446.33j,k
j
c
e
p = 0.02 p = 0.002 p = 0.006 p = 0.02
p = 0.003 p>0.05 p>0.05
p = 0.01 p
Department of Dermatology, Department of Neurology, 3 Department of Pathology, Namık Kemal University Research Hospital, Poliklinigi Tunca Cad. 100, Yıl mah, Tekirdag, Turkey 2
Gamze ERFAN1 Recep ALP2 Sule ALBAYRAK1 Keriman OGUZ2 Serkan KALAYCI1 Meltem OZNUR3 Mustafa KULAC1
1. Preskorn SH. Duloxetine. J Psychiatr Pract 2004; 10: 375-85. 2. Gross CM, Klöcker M, Jakob T, Klecha D. Dermatological side effects during therapy with serotonin noradrenaline reuptake inhibitors. Nervenarzt 2008; 79: 1307-9. 3. Vey EL, Kovelman I. Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey. J Forensic Leg Med 2010; 17: 175-85. 4. Mallinckrodt CH, Prakash A, Andorn AC. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006; 40: 33748. 5. Strawn JR, Whitsel R, Nandagopal JJ, Delbello MP. Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine. J Child Adolesc Physchopharmacol 2011; 21: 91-2. 6. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111-8. 7. Arimone Y, Bidault I, Dutertre J-P. Update of the French drug reaction assessment method. Therapie 2011; 66: 517-25. doi:10.1684/ejd.2014.2491
Changes of serum lipocalin-2 and retinol binding protein-4 levels in patients with psoriasis and Behc¸et’s disease The correlation between psoriasis, Behc¸et’s Disease (BD) and metabolic syndrome (MetS) is related to chronic inflammation [1, 2]. It is suggested that the inflammation that is caused by increased cytokines leads to an increase in insulin resistance and MetS. It has been shown that Lipocalin-2 (LCN-2), and Retinol-binding protein-4 (RBP-4) are related to obesity and insulin-resistance in humans [3, 4]. The current study aimed to investigate LCN-2 and RBP-4 levels in psoriasis and BD, which are known to have activity in insulin resistance and MetS formation. A total of 60 patients, 30 with psoriasis vulgaris and 30 with BD, admitted to the dermatology policlinics, and 30 healthy volunteers, 15 males and 15 females, who were matched according to body mass index (BMI) and age, were included in the study. The controls were individuals admitted to the EJD, vol. 25, n◦ 2, March-April 2015
hospital for an annual check-up who had no systemic and neurological diseases in their past medical and family history, systemic drug use, alcohol or narcotic drug use, and who were similar with the study group according to age, gender, and BMI. Serum LCN-2/NGAL and RBP-4 levels were determined using commercial kits with the sandwich ELISA method (for LCN-2/NGAL, BOSTER trademark, catalogue number: EK0853; for RBP-4, Assaypro trademark, catalogue number: ER3005-1). Demographic, clinical and laboratory characteristics of the psoriasis and BD patients and the control group are demonstrated in table 1. Serum LCN-2 levels in patients with psoriasis and BD were found to be statistically higher when compared to the controls (p = 0.01 and p0.05 p>0.05 p>0.05 a p = 0.006 p>0.05
HDL-cholesterol* (mg/dl) VLDL-cholesterol* (mg/dl)
47.90 ± 15.08 24.46 ± 13.92
44.64 ± 10.30b 29.33 ± 12.80c
51.18 ± 11.80b 20.13 ± 9.16c
b
Total cholesterol* (mg/dl) HbA1c* (%)
189.03 ± 33.753d 4.73 ± 0.43
175.23 ± 45.33 4.67 ± 0.33e
166.13 ± 28.82d 4.88 ± 0.38e
d
Insulin* (IU/mL) C-peptid* (ng/mL) HOMA-IR values*
5.48 ± 3.84f 2.01 ± 0.68 1.14 ± 0.79
7.66 ± 6.52 2.40 ± 1.10 1.46 ± 1.36
9.17 ± 5.17f 2.02 ± 0.90 1.88 ± 1.24
f
LCN-2* (pg/mL)
5729.06 ± 1075.56g,h
189.53 ± 2166.36h,ı
4623.37 ± 21.78.38g,ı
g
RBP-4* (ng/mL)
3284.33 ± 1028.87j
2973.00 ± 699.57k
2482.41 ± 446.33j,k
j
c
e
p = 0.02 p = 0.002 p = 0.006 p = 0.02
p = 0.003 p>0.05 p>0.05
p = 0.01 p
